Zydus Lifesciences has gained 32% in 2026, helped by favourable US FDA inspections, resilient India growth and a strong pipeline, but US weakness and margin pressure remain key risks.
Market Samachar is a news aggregator. This article was originally published by mint - markets. Tap the button above to read the full story on their site.